Table 3.
Multivariate logistic regression analysis to identify independent predictors of immunologic recovery
| Parameter | All 102 patients |
73 Advanced patients |
||
|---|---|---|---|---|
| Adjusted OR (95% CI) | p value | Adjusted OR (95% CI) | p value | |
| TMP/SMX use | 0.99 (0.28-3.51) | 0.985 | NA | NA |
| Opportunistic infections at the start of HAART | 0.28 (0.10-0.83) | 0.022 | 0.28 (0.08-0.94) | 0.039 |
| Baseline CD4 T cell count ≥ 200 cells/mm3 | 19.83 (3.73-105.48) | < 0.001 | NA | NA |
| Baseline CD4 T cell count ≥ 100 cells/mm3 | NA | NA | 2.61 (0.81-8.40) | 0.107 |
| CD4 slope ≥ 20/mm3/mon during 0−12 mon after HAART | 10.41 (3.32-32.61) | < 0.001 | 10.10 (3.06-33.30) | < 0.001 |
OR, odds ratio; CI, confidence interval; TMP/SMX, trimethoprim/sulfamethoxazole; NA, not applicable; HAART, highly active antiretroviral therapy.